Hospital Universitario Reina Sofia -ko ikertzaileekin lankidetzan egindako argitalpenak (46)

2023

  1. AG5 is a potent non-steroidal anti-inflammatory and immune regulator that preserves innate immunity

    Biomedicine and Pharmacotherapy, Vol. 169

  2. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2022

  1. The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients

    Frontiers in Oncology, Vol. 12

2021

  1. Cemented dual mobility cup for primary total hip arthroplasty in elder patients with high-risk instability

    Geriatrics (Switzerland), Vol. 6, Núm. 1

  2. Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial

    Blood Advances, Vol. 5, Núm. 3, pp. 760-770

  3. The mutational landscape of acute myeloid leukaemia predicts responses and outcomes in elderly patients from the pethema-flugaza phase 3 clinical trial

    Cancers, Vol. 13, Núm. 10

2017

  1. Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic-refractory congestive heart failure: the SEMI-SEC project

    ESC Heart Failure, Vol. 4, Núm. 2, pp. 130-137

  2. Hiponatremia e insuficiencia cardiaca congestiva refractaria a tratamiento diurético. Utilidad del tolvaptán

    Revista Clinica Espanola, Vol. 217, Núm. 7, pp. 398-404

2015

  1. Clinical and radiological short-term complications after single-stage bilateral uncemented total hip arthroplasty

    Musculoskeletal Surgery, Vol. 99, Núm. 1, pp. 67-73

  2. Validity of magnetic resonance arthrography as a diagnostic tool in femoroacetabular impingement syndrome

    Revista Espanola de Cirugia Ortopedica y Traumatologia, Vol. 59, Núm. 4, pp. 281-286

2012

  1. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

    Leukemia, Vol. 26, Núm. 7, pp. 1517-1526

2011

  1. Deregulation of FGFR1 and CDK6 oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the MIR9 family

    British Journal of Haematology, Vol. 155, Núm. 1, pp. 73-83

  2. Epigenetic activation of SOX11 in Lymphoid Neoplasms by Histone modifications

    PLoS ONE, Vol. 6, Núm. 6

  3. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in Acute Lymphoblastic Leukemia

    PLoS ONE, Vol. 6, Núm. 2

  4. LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome

    Haematologica, Vol. 96, Núm. 7, pp. 980-986

2010

  1. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia

    PLoS ONE, Vol. 5, Núm. 8

  2. Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia

    Cancer Science, Vol. 101, Núm. 2, pp. 425-432

  3. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma

    Blood, Vol. 116, Núm. 14, pp. 2531-2542

2009

  1. A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms

    PLoS ONE, Vol. 4, Núm. 9

  2. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia

    European Journal of Cancer, Vol. 45, Núm. 10, pp. 1877-1889